Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/42042
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBoscheck, Ralfen_US
dc.date.accessioned2010-12-01T09:41:31Z-
dc.date.available2010-12-01T09:41:31Z-
dc.date.issued2008en_US
dc.identifier.citation|aIntereconomics |c0020-5346 |v43 |y2008 |h5 |p277-281en_US
dc.identifier.pidoi:10.1007/s10272-008-0261-z-
dc.identifier.urihttp://hdl.handle.net/10419/42042-
dc.language.isoengen_US
dc.subject.ddc330en_US
dc.subject.stwArzneimittelrechten_US
dc.subject.stwVerbraucherschutzen_US
dc.subject.stwPharmazeutisches Produkten_US
dc.subject.stwDeregulierungen_US
dc.subject.stwGesundheitswesenen_US
dc.subject.stwUSAen_US
dc.subject.stwDeutschlanden_US
dc.titleOff-label drugs vs. the merits of centralised regulatory controlen_US
dc.type|aArticleen_US
dc.identifier.ppn582112257en_US
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungenen_US

Files in This Item:
File
Size
50.61 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.